[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tb":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639596","tb-stigma-in-the-uk-patients-experiences-and-everyday-responses-100639596",false,"NCT07609264","TB Stigma in the UK: Patients Experiences and Everyday Responses","Making Sense of Tuberculosis (TB) Related Stigma in a Low-incidence Area of the UK: Patients Experiences and Everyday Responses","TB stigma","This study seeks participants who have been diagnosed with pulmonary TB, extrapulmonary TB, latent TB infection (LTBI), and drug sensitive or drug resistant TB within the last 10 years. Participants may have different cultural and socioeconomic backgrounds and will be resident within a pre-defined TB low-incidence coastal\u002Frural area of the UK.\n\nInclusion criteria\n\n* Aged 18 or over at start of study\n* Resident in rural or coastal areas within South or Southwest England\n* Diagnosed with either active or latent TB within the last 10 years\n\nExclusion criteria\n\n* Lacks mental capacity or is unwilling to consent to participate in the study\n* Under 18 years of age\n* Lives in an area of TB high-incidence (above 10 cases\u002F100,000 population) or outside of rural and coastal areas of South\u002FSouthwest England","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","Public understanding of tuberculosis (TB) is shaped by sociocultural norms, educational background, and personal experiences. Misconceptions about TB transmission, disease severity, and treatment side effects are widespread, contributing to stigma and fear of social rejection. Such stigma can lead individuals to conceal their diagnosis, limiting access to support, engagement with healthcare, and overall health literacy.\n\nTB-related stigma is recognised as a significant barrier to ending the global TB epidemic, affecting quality of life and access to care. Yet in high-income, low-incidence (HILI) countries like the UK, its prevalence, influence, and lived impact remain largely unexplored. Where stigma appears in research, it is often treated as an emerging theme, leaving a critical gap in understanding how individuals with TB, or those caring or supporting them, experience and respond to it.\n\nThis study adopts a Constructivist Grounded Theory (CGT) approach to examine TB-related stigma in depth. CGT allows the research to explore how people living with TB make sense of, interpret, negotiate, and resist stigma, capturing the dynamic and contextual ways it shapes their lives, identities, and interactions with healthcare systems. By investigating these meaning-making processes, the study aims to illuminate how stigma operates in the UK, providing insights to inform future stigma-reduction interventions, communication strategies, and supportive healthcare practices, ultimately benefiting patients, communities, and the NHS.",[25,26,27,28,29],"TB","Tuberculosis","Stigma","TB Stigma","Low Incidence",[25,26,27,31,15],"Low incidence","NOT_YET_RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":21},"2026-09-01",{"date":40,"type":21},"2028-03-01",{"name":42,"class":43},"Bournemouth University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100605609","parent-study-name-pulmonary-rehabilitation-to-reduce-post-tuberculosis-morbidity-tb-pure-100605609","NCT07164742","Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)","Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB PURE) A Randomized Multi-Centre Trial","TB Pure","Inclusion Criteria:\n\n* Age at least 18 years\n* Microbiologically confirmed (smear microscopy, GeneXpert or culture) pulmonary TB disease\\*\n* Not completed more than 2 weeks of TB treatment\n* Receiving TB care at the outpatient clinics at the TB PuRe study sites\n* Willingness to complete 48 weeks of study evaluations.\n* Access to a smartphone.\n\nExclusion Criteria:\n\n* Modified Medical Research Council score of 0 points (dyspnea only with strenuous exercise)\n* Multi or extensively drug-resistant TB disease\\*\n* Extrapulmonary TB disease at any clinical sites without pulmonary involvement\n* TB meningitis or TB of the spine\n* Symptomatic cardiovascular disease, including coronary artery disease, arrhythmias and congestive cardiac failure.\n* Karnofsky Score \\\u003C 40 points\n* Any medical condition that prevents pulmonary rehabilitation eg: fracture of lower\u002Fupper limbs\u002Fpregnancy\n* Bronchodilators and\u002For corticosteroids inhaled or otherwise.",{"count":54,"type":21},690,"INTERVENTIONAL",[57],"NA","Individual-level, unblinded randomized controlled trial of an 8-week (short arm) or 24-week (extended arm) pulmonary rehabilitation program, relative to standard of care, to prevent post-tuberculosis respiratory morbidity. Randomization will occur in a 1:1:1 ratio at the initiation of treatment.",[60,25,61],"TB - Tuberculosis","TB Infection",[63,64,65,66],"pulmonary tuberculosis","Pulmonary Rehabilitation","post-tuberculosis respiratory morbidity","Drug-sensitive TB","RECRUITING","2026-03-25",{"date":70,"type":36},"2026-03-27",{"date":72,"type":36},"2026-03-18",{"date":74,"type":21},"2028-09-15",{"name":76,"class":43},"Johns Hopkins University",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":55,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100569966","phase-1-pharmacokinetic-study-of-sudapyridinewx-081in-healthy-chinese-subjects-100569966","NCT06701110","Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects","Pharmacokinetics and Mass Balance Study of WX-081 (Sudapyridine) in Healthy Chinese Volunteers","Inclusion Criteria:\n\n* Healthy adult males. Age: 18-45 years (inclusive). Body weight: BMI between 19.0 and 26.0 kg\u002Fm² (inclusive), with body weight not less than 50.0 kg.\n\nVoluntarily signed the informed consent form. Able to communicate effectively with investigators and comply with the study protocol.\n\nExclusion Criteria:\n\n* Clinically significant abnormalities identified through physical examination, vital signs, laboratory tests (e.g., blood count, biochemistry, troponin, coagulation function, urinalysis, fecal occult blood), thyroid function, 12-lead ECG, chest X-ray, rectal examination, or abdominal ultrasound (liver, gallbladder, pancreas, spleen, kidney).\n\nProlonged corrected QT interval (QTcF) \\> 450 msec on 12-lead ECG. Positive results for hepatitis B surface antigen (HBsAg or HBeAg), hepatitis C antibody (HCV-Ab), syphilis antibody, or HIV antigen\u002Fantibody (HIV-Ag\u002FAb).\n\nUse of drugs that inhibit or induce hepatic enzymes or transporters within 30 days prior to screening.\n\nUse of prescription or over-the-counter medications, herbal remedies, or dietary supplements (e.g., vitamins, calcium) within 14 days prior to screening.\n\nAny clinically significant disease or condition that may affect study results, including but not limited to cardiovascular, respiratory, endocrine, neurological, gastrointestinal, urinary, hematological, immune, psychiatric, or metabolic disorders.\n\nConditions that could affect drug absorption, such as a history of gastric surgery (e.g., gastrectomy, gastric bypass), gallbladder removal, or inflammatory bowel disease.\n\nHistory of organic heart disease, heart failure, myocardial infarction, angina, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, long QT syndrome, or family history of sudden cardiac death due to cardiac reasons.\n\nMajor surgery within 6 months prior to screening or incomplete surgical wound healing.\n\nKnown hypersensitivity or allergy to two or more substances, or potential allergy to the investigational drug or its excipients (e.g., lactose, low-substituted hydroxypropyl cellulose, sodium lauryl sulfate, silicon dioxide, magnesium stearate).\n\nHemorrhoids or perianal conditions with regular or current rectal bleeding.",true,"MALE","45 Years",{"count":89,"type":21},10,[91],"PHASE1","This single-center, open-label, non-randomized study aims to evaluate the pharmacokinetics, mass balance, and metabolic pathways of WX-081 (Sudapyridine) following a single oral dose of \\[U-14C\\] WX-081 in healthy Chinese male volunteers. A total of 6-10 subjects will be enrolled to obtain complete samples and data from at least six participants. Biological samples, including blood, plasma, urine, and feces, will be collected over a specified time period. The study will assess pharmacokinetic parameters, excretion pathways, and identify major metabolites contributing to over 10% of plasma exposure.",[25],"2024-11-20",{"date":96,"type":36},"2024-11-22",{"date":98,"type":36},"2024-09-04",{"date":100,"type":21},"2026-06-12",{"name":102,"class":103},"Shanghai Jiatan Pharmatech Co., Ltd","INDUSTRY",""]